High MCT1 expression levels were shown to be significantly implicated in a decreased overall survival (OS) of patients with bladder cancer [74,75], RCC [61], melanoma [41], endometrial cancer [43], soft-tissue sarcoma [45], ESCC [62,63], head and neck cancer [46], osteosarcoma [30], SCLC [35], synovial sarcoma [49], adrenocortical carcinoma [50], gastric cancer [67], breast cancer [73] and T-cell NHL [64], remaining as an independent prognostic factor for OS in half of these studies [43,46,49,61,62,63,67,74]. Here, SLC16A1 is linked to head and neck cancer.